TAK, US8740602052

Analyst consensus raises target for Takeda stock to USD 20.74

Published on 10/27/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Takeda reports fiscal second-quarter results on October 29. Takeda stock costs EUR 18.50 on October 27, 2026, up 2.21 percent versus the Tradegate close.

Analyst target and reporting date

TradingView reported on October 15, 2026 that the average analyst target rose from USD 20.58 to USD 20.74.
Takeda will present fiscal second-quarter 2026 results on October 29, 2026.
Takeda stock costs EUR 18.50 at Lang & Schwarz on October 27, 2026 at 3:12 p.m. CEST, 2.21 percent above the Tradegate close of October 26, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical Company Limited (ISIN US8740602052) is heading into its October 29 results with the average analyst target raised from USD 20.58 to USD 20.74. TradingView reported the consensus change on October 15, 2026, based on 14 analysts. At Lang & Schwarz, the stock was trading at EUR 18.50 on October 27, 2026 at 3:12 p.m. CEST, up 2.21 percent versus the Tradegate close of October 26, 2026 at EUR 18.10.

Target moves above the market

The revised USD 20.74 average target is 11.09 percent above the USD 18.67 U.S. price cited in the TradingView assessment on October 14, 2026. The same report said the consensus rating remained Buy across 17 analysts, including 10 Buy ratings and 7 Hold ratings.

Stock sits near its yearly high

Takeda's U.S. quote stood at USD 20.32 at 2:29 p.m. UTC on October 27, 2026, while its 52-week range was USD 12.99 to USD 20.55. The market capitalization was USD 64.7 billion and the price-to-earnings ratio was 57.11 on that date. The euro quotation therefore sits below the upper end of the dollar range, but the currencies are not combined in one performance calculation.

Results arrive on October 29

Takeda announced on October 15, 2026 that it would present fiscal second-quarter 2026 results on October 29. The company said the presentation and question-and-answer session would run from 7:00 p.m. to 8:15 p.m. JST. Takeda also identified the event as the release date for its fiscal second-quarter results.

Comparison with peers

Takeda: up 2.21 percent in EUR, P/E 57.11, market capitalization USD 64.7 billion. Pfizer (NYSE, USD): down 0.18 percent, P/E 39.25, market capitalization USD 169.5 billion. GSK (NYSE, USD): down 0.10 percent, P/E 16.10, market capitalization USD 102.3 billion. These figures are dated October 27, 2026.

What the next report will clarify

The October 29 release will put the target revision against Takeda's latest operating figures. MarketBeat reported that Takeda's most recent quarter produced USD 7.50 billion in revenue and USD 0.95 adjusted earnings per share, against consensus of USD 7.13 billion and USD 0.41, respectively.

Price stays close to the upper range

The current euro quotation is EUR 18.50 at Lang & Schwarz on October 27, 2026 at 3:12 p.m. CEST, 2.21 percent above the Tradegate close of October 26, 2026 at EUR 18.10. The further course of trading is shown by the continuously updated real-time quote of Takeda stock.